Navigation Links
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Date:10/29/2010

2012E
2013E   Revenue
$253
$295
$359
$409   Adjusted Cash EBITDA
$29
$39
$59
$105  
Net Cash Flow Prior to Financing
($2)
($19)
$25
$78 Forward Looking Statements Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.  Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regu
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
2. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
8. Angiotech announces positive results from Bio-Seal(TM) clinical study
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
11. Angiotech announces date of annual general meeting of shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Whitehouse Laboratories is ... the Parenteral Drug Association (PDA) to host ... on container closure integrity testing. This lecture/laboratory course will ... and philosophies detailed in the recently proposed revision to ... The course will span container closure integrity testing (leak ...
(Date:9/29/2014)... 30, 2014 Each year in ... require medical attention. In the military, burn injury ... to battlefield medical care. More than 800 service ... Burn wounds heal slowly, remain inflamed and often ... physically debilitating and functionally damaging. While developments in ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of the ... of cartilage repair, regeneration, allograft reconstruction and research ... the world gathered to discuss the future of ... of Regenerative Medicine symposium, Cartilage Regeneration: State ... included Orthopedic Biosurgery, Minced Juvenile Allograft, and State ...
(Date:9/29/2014)... emerging diseases and biodiversity loss requires evolutionary thinking, ... Science Express that was co-authored by Bruce ... Agriculture and Life Sciences. , For the first ... reviewed progress in addressing a broad set of ... approaches that consider evolutionary histories and the likelihood ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Faster Healing with Fewer Scars 2World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3
... Kansas to its annual promotional campaign of biotechnological, pharmaceutical and medical device companies ... , , (Logo:   ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... July 29 Omeros Corporation (Nasdaq: OMER ) ... facility under which it may sell up to $40 ... Opportunity, Ltd. (the "investor") over a 24-month period. Omeros is ... enter into and consummate other equity, debt and non-dilutive financing ...
... ,, LONDON , ... pleased,to announce the appointment of Dr Neill Moray Mackenzie ... to CMPT a long record of executive,board level management ... Genetics Ltd, Oxford Biomedica plc (an LSE,listed company), Avidex ...
Cached Biology Technology:BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 2CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 5
(Date:9/30/2014)... Munich report that a new class of chemical ... drugs. They have also pinpointed the relevant target ... agents. , Researchers led by LMU,s Professor ... Technische Universitt Mnchen have identified a class of ... the fight against malignant tumors. The compound is ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the American Association of Immunologists 2013 ... from July 13-18, 2013. These awards are meant ... scientists from underrepresented groups into the mainstream of ...
... progress in the search for the first broad-spectrum drugs ... common infectious diseases. Their study on these potential drugs ... the journal ACS Medicinal Chemistry Letters . ... HRV infections cause mild disease, they can lead to ...
... teachers to sing melodies accurately, according to a new ... the University of Kaiserslautern in Germany. Their analysis of ... songbirds, brain processes. The work is published online in ... is considered to be one of the most complex ...
Cached Biology News:Songbirds turn on and tune up 2
Recombinant Feline IFN-alpha...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Biology Products: